Medicare AdvantageDocumentationMedium impact
MA08.065k, Octreotide Acetate (Sandostatin® LAR Depot)
Independence Blue Cross·Endocrinology, Gastroenterology, Oncology +1 more·Pharmacy
Effective date
Aug 18, 2025
We identified it
Jun 19, 2026
Summary
MA08.065k updates medical necessity criteria and medical coding requirements for Octreotide Acetate (Sandostatin® LAR Depot) effective immediately. The billing team must review the new medical necessity standards and ensure coding compliance to avoid claim denials on Medicare Advantage plans.
Action Required
By August 18, 2025: Billing team must obtain and review the full MA08.065k policy text from the provided URL to identify specific medical necessity criteria changes and updated coding requirements for Octreotide Acetate. Update billing system rules and provider encounter templates to reflect new medical necessity documentation requirements. Notify providers prescribing this medication of documentation changes needed to support claims. Flag all Octreotide Acetate claims for review against updated criteria until team confirms understanding of changes. Failure to apply updated medical necessity criteria will result in claim denials.